Keith W. Crawford, PhD, RPh

Keith W. Crawford, PhD, RPh

National Institutes of Allergy and Infectious Diseases

Program Officer
Drug Development and Clinical Sciences Branch
Therapeutic Research Program
Division of AIDS
National Institutes of Allergy and Infectious Diseases



  • Cornell University, Ithaca, N.Y. 1978-1982, B.S., Biology
  • Temple University School of Pharmacy, Philadelphia, PA. 1982-1985, B.S, Pharmacy
  • Uniformed Services University of the Health Sciences, Bethesda, Md. 1986-1992, Ph.D., Pharmacology
  • Johns Hopkins Bloomberg School of Public Health and Hygiene 2008-10, Coursework in the Graduate Training Program in Clinical Investigation (GTPCI)


  • Residency in Clinical Pharmacy, Pharmacy Dept., National Institutes of Health, Warren G. Magnusen Clinical Center 1985-1986
  • Staff Fellow, Section on Pharmacology, Laboratory of Biochemical Pharmacology, National Institute of Diabetes Digestive and Kidney Disease 1992-1995

Selected Publications

  1. Godfrey, C; Thigpen, M., Crawford, K.W., et al.  Global HIV Drug Resistance: A Pespective and Report of a NIAID consultation.Journal of Infectious Diseases, 2017,  (available online)
  2. Jean-Phillipe, P., Gnanashamugam, D, Speigel, H., Crawford, K.W. et al. HIV Birth Testing and Linkage to Care for HIV Infected Infants: Workshop Synopsis. AIDS, 2017, in press
  3. Crawford, K.W., Wakabi, S., Kibuuka, H., Magala, F., Keshinro, B., Okoye, I., Akintunde, E., Hamm, T. East Meets West: A Description of HIV-1 Drug Resistance Mutation Patterns of Patients failing First Line Therapy in PEPFAR-clinics from Uganda and Nigeria. AIDS Research and Human Retroviruses, 2014, 30(8):796-9
  4. Crawford, K.W., Wakabi, S., Kibuuka, H.,Magala, F., Liu, M., Hamm, T. Evaluation of Treatment Outcomes for Patients on First-Line Regimens in US Presidents Emergency Plan for AIDS Relief (PEPFAR) Clinics in Uganda: Predictors of Virologic and Immunologic Response from RV288 Analyses. HIV Medicine, 2014, 15 (8):470-78
  5. Crawford K.W., Njeru D, Maswai J, Omondi M, Apollo D, Kimetto J, Gitonga L, Munyao J, Langat R, Aoko A, Tarus J, Khamadi S, Hamm TE  Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy. AIDS, 2014, 28(3):442-5.
  6. Crawford,K.W., Li,X., Xu X.,Abraham,A., Dobs, A., Margolick,J.,  Pallella, F., Kingsley,L., Witt,M.,  Brown, T. Lipodystrophy and Inflammation Predict Grip Strength in HIV-infected Men: the MACS Body Composition Substudy. AIDS Research and Human Retroviruses, 2013, 29(8):1138-45.
  7. Crawford, KW, Ripin, DHB Levin, A, Flexner, C; Optimizing The Manufacturing, Formulation, and Dose of Antiretroviral Drugs for more Cost-efficient Delivery in Resource-constrained Settings: A Consensus Conference. Lancet Infectious Diseases, 2012, 12:550-60
  8. Crawford, K.W. and Flexner, C., Does Dosing frequency Matter with Antiretroviral Drugs?, Treatment Strategies–AIDS,2010,1:34-39 (
  9. Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; and for the ACTG A5211 Study TeamPharmacokinetic/pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5  Antagonist Vicriviroc in the Treatment-Experienced HIV Patients. Journal of the Acquired Immune Deficiency Syndrome, 2010, 53 (5):598-605
  10. Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C; AIDS Clinical Trials Protocol 5015 Team. Age-related Changes in the Plasma Concentrations of the HIV Protease Inhibitor Lopinavir. AIDS Research and Human Retroviruses, 2010, 26:635-643